Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...
Le Lézard

Newron Provides Update Following Type A Meeting With the FDA

Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral ...
TelecomTV

Cohere Technologies lands $28m FutureG deal for ISAC R&D

FutureG Office is investing in cutting-edge, next-gen techIt has handed $28m in funding to Cohere Technologies for the ...

Cohere Technologies Wins $28 Million U.S. Government Contract to Develop Multi-Waveform RAN for ISAC

Multi-Waveform Wireless Prototype Will Deliver Operational Aerial Surveillance and Response ISAC is a mission-first ...

Spontaneous current loops in a kagome metal point to hidden quantum order

Quantum materials, materials exhibiting physical behavior governed by the laws of quantum mechanics, have proved promising ...

Light flips bacterial signaling enzyme between two shapes, unlocking how signals travel

Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...
JCN Newswire

Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))

Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer’s disease (AD) research, including lecanem ...